The CorEvitas Psoriasis (PSO) Registry

About

Brief Summary

The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.

Study Type

Observational

Eligibility

Gender

All

Healthy Volunteers

No

Minimum Age

18 Years

Maximum Age

N/A

ELIGIBILITY CRITERIA∗ To be eligible for enrollment into the CorEvitas Psoriasis Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below.

Inclusion Criteria:

The patient must:

Have been diagnosed with psoriasis by a dermatologist.
Be at least 18 years of age or older.
Be willing and able to provide written consent for participation in the registry.
Be willing and able to provide Personally Identifiable Information (PII) that includes the following types of personal information at a minimum: 1) Full Name and 2) Date of Birth.
Meet one of the following criteria. Have started on or switched to a systemic psoriasis treatment within the previous 12 months†▲:

Exclusion Criteria:

Patient is participating in or planning to participate in a double-blind randomized of a psoriasis drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded.

Join this Trial

Enrolling by Invitation

These studies are not open to everyone who meets the eligibility criteria, but only to people in that particular population, who are specifically invited to participate.

Share:

Study Stats

Protocol No.

23-5141